Markers of response to CDK4 & 6 inhibition from neoMONARCH: A phase II neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive, HER2 negative breast cancer

被引：1
|
作者：
Hurvitz, S.
Martin, M.
Wijayawardana, S.
Brahmachary, M.
Ebert, Pj
Young, S.
Jansen, V.
Slamon, D.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P3-10-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-10-08
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer cells
    Guarducci, C.
    Nardone, A.
    Feiglin, A.
    Migliaccio, I.
    Malorni, L.
    Bonechi, M.
    Benelli, M.
    Di Leo, A.
    Hodgson, G.
    Shapiro, G.
    Brown, M.
    Jeselsohn, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [42] Predictors of Response to Standard Neoadjuvant Chemotherapy in Estrogen Receptor Positive, HER2 Negative Breast Cancer
    Bhargava, R.
    LABORATORY INVESTIGATION, 2012, 92 : 26A - 26A
  • [43] Predictors of Response to Standard Neoadjuvant Chemotherapy in Estrogen Receptor Positive, HER2 Negative Breast Cancer
    Bhargava, R.
    MODERN PATHOLOGY, 2012, 25 : 26A - 26A
  • [44] CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer
    Migliaccio, Ilenia
    Bonechi, Martina
    McCartney, Amelia
    Guarducci, Cristina
    Benelli, Matteo
    Biganzoli, Laura
    Di Leo, Angelo
    Malorni, Luca
    CANCER TREATMENT REVIEWS, 2021, 93
  • [45] Real-world experience using exemestane and everolimus in patients with hormone receptor positive/HER2 negative breast cancer with and without prior CDK4/6 inhibitor exposure
    Lupichuk, S. M.
    Recaldin, B.
    Nixon, N. A.
    Mututino, A.
    Joy, A. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [46] A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer
    Mattar, Andre
    Goncalves, Rodrigo
    Ellis, Matthew J.
    Hegg, Roberto
    CANCER RESEARCH, 2015, 75
  • [47] Adjuvant palbociclib plus endocrine therapy for hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study
    Mayer, Erica L.
    DeMichele, Angela M.
    Guo, Hao
    Miller, Kathy D.
    Rugo, Hope S.
    Schneider, Bryan
    Waks, Adrienne G.
    Come, Steven E.
    Mulvey, Theresa
    Bartlett, Cynthia Huang
    Koehler, Maria
    Barry, William
    Winer, Eric P.
    Burstein, Harold J.
    CANCER RESEARCH, 2018, 78 (04)
  • [48] The Mutational Landscape of 1172 Patients with Hormone Receptor-Positive, HER2-negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
    Shah, Ami N.
    Lim, Bora
    Mita, Monica M.
    Mauer, Elizabeth
    Layng, Kayla V.
    Chao, Calvin
    Brufsky, Adam M.
    CANCER RESEARCH, 2023, 83 (05)
  • [49] Real World Statistics on CDK4/6 Inhibitor Use in Metastatic Hormone Receptor Positive and HER2-Negative Breast Cancer with a Focus on Age
    Monahan, Kathleen
    Kamaraju, Sailaja
    Cheng, Yee Chung
    Retseck, Janet
    Sriram, Deepika
    Burfeind, John
    Chitambar, Christopher
    Chaudhary, Lubna N.
    CANCER RESEARCH, 2023, 83 (05)
  • [50] Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities
    Lloyd, Maxwell R.
    Spring, Laura M.
    Bardia, Aditya
    Wander, Seth A.
    CLINICAL CANCER RESEARCH, 2022, 28 (05) : 821 - 830
12345